Try our Advanced Search for more refined results
Life Sciences - December, 2014
247 articles
- Covidien, Medtronic Settle Investor Suit Over $42.9B Merger
- Actavis Jumped Gun On Allergan Eye Drug ANDA, Judge Says
- Deals Rumor Mill: Stryker, HeidelbergCement, BeijingWest
- FDA Plans To Alter Lifetime Ban On Gay Male Blood Donation
- Fed. Circ. Ruling Moots Derivative Suit, Zimmer Tells Chancery
- Court OKs Medtronic Payments For Board's Inversion Taxes
- Ex-NFLer Wants SEC Claims Sacked From Pump-Dump Claim
- Plaintiff Asks Fla. Judge To Deny Stiefel's Recusal Request
- Judge Pauses NY AG's Actavis Injunction Amid Appeal
- J&J Penalties Help US Atty's Office Pull In $2.3B In FY 2014
- PTAB Nixes 'Recycled' Bid For AIA Review Of Suboxone Patent
- Oscar Winner Nabs $1M Deal Win After Sensa Attys Quit
- Ex-Orioles Player Says Newman Strikes Out Insider Charges
- 3 Life Sciences Cos. Tune IPO Plans Ahead Of New Year
- 5 NJ Accutane Suits Survive Timeliness Challenge
- Stryker Can't Shake Suit Over Bone Medical Devices
- FDA Hints At Legal Action Against Powdered Caffeine Sales
- ITC Says Indian IP, Investment Policies Stifling US Biz
- DOJ Intervenes In FCA Suits Accusing Omnicare Of Kickbacks
- Nixon Peabody, Mintz Levin Blitz Biotech's Legal Mal Suit
- Paris Appeals Court Backs €40.6M Antitrust Fine For Sanofi
- FDA Digs In Heels On Orphan Drug Exclusivity
- SEC Launches Insider-Trading Suit Over $3.3B Abbott Deal
- FTC Report Finds Decline In Potential Pay-For-Delay Deals
- SEC Fines Calif.-Based Atty For Trading On Client's Intel
- Nexium Buyers Call Appeal Dismissal Bid 'Gamesmanship'
- FTC Approves $5.4B Eli Lilly-Novartis Deal With Divestiture
- JPML Asked To Combine Suits Over Daiichi's Benicar In Ohio
- Amazon Fights Class Action On Dangerous Diet Drug Sales
- PTAB Nixes Warsaw Spine Implant Patent In AIA Review
- The Biggest M&A Moments Of 2014: Second Half
- Judge Denies Class Cert. In Cymbalta Withdrawal Risks Suit
- J&J Could Pay Out Up To $700M In Deal To Boost Cancer Biz
- UConn Health Center Must Name Researchers Sought By PETA
- Product Liability In 2014: What Did And Didn't Happen?
- Judge Won't Alter Atty's 17-Year Stock Scheme Sentence
- The State Of Technology-Assisted Review In 2014
- Law360 Names Law Firms Of The Year
- Law360 Names Practice Groups Of The Year
- Ch. 11 Case For Skin Treatment Co. Thrown Out
- Growth Hormone Biotech Seeks $86M IPO Amid Strong Market
- Mylan Can Ask Fed. Circ. To Weigh Hatch-Waxman Jurisdiction
- K&L Gates Lands Deals Ace From LipoScience In NC
- Becton Didn't Hold Monopoly Power, Judge Rules
- EU Approves €385M IMS-Cegedim Deal Pending Fixes
- SG Says High Court Shouldn't Hear Teva Drug Label Case
- Reckitt Asks Judge To Again Consider Axing Suboxone Suit
- 5 IPOs Reap $1B In Last Full Week Of Record-Busting 2014
- Teva, Pliva Ask High Court To Weigh Pa. Reglan Preemption
- Player Recruiter Pleads Guilty In Biogenesis Doping Case
- Fed. Circ. Slashes Stryker's $210M Patent Damages Award
- Good Luck Guessing With The Gov't On Gainsharing
- Feds Won't Interfere With States' Medical Marijuana Laws
- Onyx Traders Say Newman Undermines SEC Insider Case
- AllPure Says Fed. Circ. Needn't Revisit Device Patent Ruling
- The Biggest M&A Moments Of 2014: First Half
- 2nd Cancer Biotech Of The Week Soars In Market Debut
- Pay-For-Delay In 2014: Courts Fill In The Actavis Gaps
- Fed. Circ. Got Original-Patent Rule Wrong, Antares Says
- Ex-Retrophin CEO Gave Away Stock, Investor Suit Says
- EU's Top Court Opens Door to Some Stem Cell Patents
- Merck Will Drop Up To $375M On Cancer Treatment Co.
- Holland & Knight Adds Fla. Health Care Policy Coordinator
- Drug Supplier In MLB Doping Scandal Pleads Guilty
- FDA Raps Sunovion Pharma For Bogus Benefit Claims
- Cancer Biotech Bellicum Soars After $140M IPO Trumps Range
- Mylan Loses 4th Challenge Of Gilead Viread Patent
- USPTO Is Rejecting Potentially Life-Saving Inventions
- Dendreon Gets Nod For Bondholder Support Deals
- Many Biotech Patents At Risk After Fed. Circ. Myriad Ruling
- Fed. Circ. Strikes Down More Myriad Cancer Test Patents
- Watson Beats Auxilium's Testim Patent Suit In Court Trial
- 8th Circ. Affirms Bayer's FCA Loss But Trims Damages
- Kline And Specter Take On Philly's Plaintiff-Friendly Rep
- Allergan Investors Accuse Valeant, Pershing Of Takeover Plot
- Advent, Avista Drop $1.5B Drug Co. Buy Amid FDA Scrutiny
- PTAB Won't Review Orthophoenix Bone Tool Patents
- Philips Puts Down $1.2B For Medical Device Manufacturer
- What Happens When Legal Aid Cuts Stimulate Pro Bono?
- FDA To Review Apotex Biosimilar Of Amgen Blockbuster Drug
- Option Deals For Biotech: Ensuring They Are Enforceable
- NECC Prez Charged With Murder Over Meningitis Outbreak
- Another Big Year For ITC: Top 12 Section 337 Highlights
- Full Fed. Circ. Won't Review Nixing Of Apotex Patent
- Order Impeded Arbitration Appeal In Avandia Fee Fight: Court
- CMS Clouds Stance On Open Payments Exemption
- New FDA Rule Will Enforce Electronic Drug Labeling
- Cancer Biotech Juno Eyes $204M IPO With Increased Terms
- Ex-Employee Accuses Abbott Of Retaliation In FCA Suit
- 8th Circ. Asked To Nix Attys' Support Of Jones Day Sanctions
- 4th Circ. Revives Challenge To Generic Celebrex Exclusivity
- FTC Says Reckitt Still Holding Back Suboxone Docs
- Biotech Acquisition Co. Prices $40M IPO
- Top FDA Aide Joins Boies Schiller's Gov't Response Team
- Drugmakers Can't DQ Cohen Milstein In Chicago Opioid Suit
- 7th Circ. Explains Role Of Objectors In Class Settlement
- Top 10 Trade Secrets Developments Of 2014: Part 1
- A Look At 2014 Fed. Circ. Cases Impacting AIA Proceedings
- SEC To Drop Insider Trading Case Over Herbalife Stock
- Actavis Can't Delay Injunction In 'Product Hopping' Case
- Chancery Halts Zimmer Investor Claims During Patent Appeal
- New USPTO Guidance Has Fewer Limits On Patent Eligibility
- Skadden Atty Testifies On Failed $21B J&J-Guidant Merger
- FTC Urges Court Not To Nix AbbVie Pay-For-Delay Suit
- High Court Clears Air On Class Action Removal Disputes
- Judge Fines Viora for Motion 'Escapade' In Syneron IP Feud
- Purdue's 'New' Oxycodone Pills Are Copycats, Acura Says
- Fed. Circ. Gives Promega 2nd Shot In $52M LifeTech IP Fight
- Forest Gets Some Relief In Lexapro Marketing MDL
- The 5 Biggest M&A Failures Of 2014
- Inside New Fed. Circ. Practice Notes For Expedited Appeals
- High Court Ruling Sets Low Bar For Class Action Removal
- FTC Centennial: How Health Care Antitrust Has Evolved
- 3 Questions To Ask Yourself Before Hiring Appellate Counsel
- NJ Bill Would Apply False Claims Act Provisions Retroactively
- Xarelto Safety Suits Sent To Louisiana By MDL Panel
- NJ State Court Tosses Hundreds Of Accutane Suits
- JPML Sends Opana Pay-For-Delay Suits To Illinois
- JPML Again Won't Combine USPlabs Diet Supplement Suits
- Civitas Therapeutics Drops IPO Plan In Wake Of Acorda Deal
- Amid Push For Growth, Danone Says $3.7B Unit Isn't For Sale
- Taxation With Representation: Hughes Hubbard, Hogan, Ropes
- 6 Questions To Ask Before An Internal Investigation
- Judge In Actavis Antitrust Suit Keeps Namenda On Market
- Dendreon Bondholder Support Deal Comes Under Fire
- FDA Warns Pfizer Geodon Drug Could Cause Deadly Rash
- AstraZeneca Drops 1st Circ. Row Over Nexium Class Cert.
- Boiron Colluded On Deal Over Flu Remedies, 9th Circ. Told
- Pa. Transit Agency Slaps Gilead With Price-Gouging Suit
- CORRECTED: PTAB Rejects Mylan's Challenge To Gilead's Viread Patent
- What Lawyer-Novelists Learned From Being Lawyers
- Patent Suit Implicating Pitt In Stealing Vaccine Tossed
- BioMed Nets $322.5M In Sale Of GSK Unit's Facility
- Fed. Circ. Won't Disturb Block On Sandoz Combigan Generic
- 11th Circ. Confirms Experts Must Prove Causation
- CMS Databases Increase Qui Tam Risk For Health Providers
- CSPI Urges FDA To Ban Powdered Caffeine Sales
- JPML Refuses To Consolidate Cymbalta Cases
- Siemens' $3.6M Settlement With HearUSA Stockholders OK'd
- Reckitt Accuses FTC Of Skirting Court's Instructions
- Actavis, NY AG Differ On Suboxone Ruling On Antitrust Suit
- Deals Rumor Mill: Danone Groupe, Vestas, Fosun International
- Life Sciences MVP: Irell & Manella's David Gindler
- 2014 Year In Review Of US Biosimilar Activity
- Abbott Asks 7th Circ. To Affirm Toss Of Off-Label Use Suit
- PTAB Backs 3 Oracea Patents In 1st-Ever Pharma AIA Ruling
- CORRECTED: Genentech Sinks Bid For AIA Review Of Cancer Drug Patent
- Fed. Circ. Hands USPTO Win In Cancer Patent Disclaimer Row
- NuVasive Again Dodges Medicare Probe Securities Class Suit
- Bidder-Activist Collaboration Will Continue To Evolve
- Lupin Fights EU's 'Wholly Novel' Pay-For-Delay Fine
- Millennium Beats IPXpharma's Cancer Drug Patent Suit
- Drunken Drivers Can't Bring BAC Tester Claims, 3rd Circ. Says
- Deals Rumor Mill: JCDecaux, Valeant, AAR Corp.
- Market Rumors: Valeant Pharmaceuticals, Santander, Ardagh
- Life Sciences MVP: Morgan Lewis' Randy Sunberg
- Juno Nears Biggest Biotech Mark With $153M IPO Plan
- CR Bard Fights Consolidation Of Suits In Pelvic Mesh MDL
- 3rd Circ. Affirms Revival Of Genaera Investor Suit
- Ebola Vaccine Makers Get Liability Immunity From HHS
- Becton Seeks Stay Of Injunction In $340M Antitrust Suit
- Gov't Paying Close Attention To Patient Assistance Programs
- Hospira Gets 4 Of 5 Cubicin Patents Nixed
- Nexium Verdict No Final Word On Pay-For-Delay
- 2014 FDA Year In Review: Food Edition
- Indian Officials Conditionally Approve $3.2B Ranbaxy Sale
- Plaintiffs' Expert In CR Bard Pelvic Mesh MDL Disqualified
- OtisMed, Ex-CEO Cop To Distributing Device After FDA Denial
- High Court Won't Review Glenmark's $16M Tarka Patent Loss
- Zoll Seeks High Court Review Of IPR Rejection Appeal Rules
- No New Trial For Two Convicted ArthroCare Executives
- Stiefel Labs Pushes For Judge's Recusal In ERISA Suit
- High Court Won't Hear Braintree's Claim Construction Appeal
- Life Sciences MVP: Fried Frank's David Shine
- Merck Keeps Pharma M&A Flowing With $9.5B Cubist Pickup
- Bayer's Flintstones Gummies Don't Boost Brains, Suit Says
- Gilead Seeks High Court Review Of Double-Patenting Row
- Fed. Circ. Says Sandoz Attack On Amgen Patents Is Premature
- Atty In NFLer Stock Scheme Sentenced To 17 Years
- Lone Biotech Braves IPO As Tech Braces For Year-End Rush
- Deals Rumor Mill: Merro, TDC, Alex & Ani
- Taxation With Representation: Skadden, Cravath, Latham
- Supplement Seller's Religion Claims Against Texas AG Tossed
- Who Is Responsible For Clinical Trial Informed Consent?
- Hagens Berman May Face Sanctions In Pa. Thalidomide Cases
- Life Sciences MVP: White & Case's Robert Milne
- Jury Hands AstraZeneca Win In Nexium Pay-For-Delay Case
- Compound Pharm Pleads Guilty To Shipping Tainted Steroids
- Minority Powerbrokers Q&A: Sanford Heisler's Felicia Medina
- En Banc 9th Circ. To Weigh FCA's Public Knowledge Bar
- Sens. Look To Block FDA Oversight Of Medical Apps
- Sandoz Urges Fed Circ. To Revive Combigan Generic Bid
- Subject Of Chancery Arrest Warrant Claims Discrimination
- FDA Tries To Tame Antitrust Wars Over Dangerous-Drug Sales
- Gov't Rejects ArthroCare Execs' 6th Amendment Claims
- Reckitt Can't Escape Antitrust Case Over 'Product-Hopping'
- Deals Rumor Mill: Oi, Fortum, Arbor Pharmaceuticals
- Fed. Circ. Reverses $176M Award In J&J Patent Row
- Chinese Regulators OK $43B Medtronic-Covidien Inversion
- BTG To Pay Up To $475M For Emphysema Treatment Maker
- Life Sciences MVP: Paul Hastings' Joe O'Malley
- NECC Ch. 11 Plan Sets Aside $135M For Outbreak Victims
- Post-Nautilus, Post-Interval: Indefiniteness In November
- Sanofi Paid $34M In Drug Kickbacks, Whistleblower Claims
- Nexium Buyers End Trial Saying AstraZeneca Paid Off Rivals
- Bausch & Lomb Violated ERISA With Execs' Payout: 2nd Circ.
- Zimmer Prevails In 1st Durom Hip Implant Trial
- Pa. High Court Won't Hear Asbestos Suits Transfer Appeal
- Dental Implant Co. Ordered To Pay $122K For Destroying Docs
- Life Sciences MVP: Kirkland & Ellis' Jay Lefkowitz
- NuVasive Ducks Atty Fees After Neurovision's $30M Jury Win
- Histogenics Misses Mark To Raise $65M In IPO
- Fed. Circ. Revives Par Pharma's Appetite Drug Patent
- Market Rumors: CGN, 1MDB, Phytotech
- FDA Overhauls Drug Risk Disclosures For Pregnant Women
- Texas Court Revives Emotional Distress Claim Against Firm
- Vitamin C Cos. Cite Motorola In 2nd Circ. Antitrust Appeal
- And Now A Word From The Panel: End Of An Era
- Ex-ArthroCare CFO Also Seeks Retrial In $756M Fraud Case
- Quarles & Brady Lands IP Partner From Kelley Drye
- Secret PTO Program Subjects Apps To Heightened Scrutiny
- No Proof Of Big Payment, AstraZeneca Says At Nexium Trial
- Market Rumors: Uber, Vale, Medtronic
- Jones Day Reps Riverside In Second Exit In Two Days
- Sigmapharm Asks Fed. Circ. For Legal Fees In Gilead IP Row
- Sophisticated Deals Attys Aren't Immune To Hackers' Guile
- 8th Circ. Spares Pliva In Generic Failure-To-Update Suit
- Omnicare, Dr. Reddy's Beat Medicare Insurer's FCA Suit
- Otsuka To Bolster Drug Pipeline With $3.5B Avanir Buy
- Stericycle Will Move Incinerator, Pay $1.2M In Utah DEQ Deal
- Mylan Challenges $4.4M IRS Deficiency Over Forest Lab Deal
- Life Sciences MVP: Sullivan & Cromwell's Matt Hurd
- Caution: Flaws Of The Attorney-To-Secretary Ratio
- So You Want To Do Business With The Saudi Government
- Medtronic Offers $17B In Bonds To Finance Covidien Deal
- Premature IP Action Over Kennedy Trust's Remicade Tossed
- FDA Boosts Warning On Biogen's MS Drug After Rare Death
- High Court Rejects Takeda Petition Over Prevacid Generic
- Ex-Va. Gov. McDonnell, Wife Lose Bid For New Trial
- Apotex Asks Fed. Circ. To Toss $76M AstraZeneca IP Win
- Companies Can't Turn Blind Eye To Whistleblowers
- 1st Circ. Nixes $30M Baxter FCA Suit Under First-To-File
- No Deal Was Reached In Mylan IP Row, Endo Tells Fed. Circ.
- GCs Name Most Arrogant Law Firms
- GCs Add 35 Firms To List Of Most Arrogant
- High Court Won't Hear Stryker's Hospital Bed Patent Case
- High Court Leaves Merck Licensing Row In Arbitration